FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $141,425 | -88.6% | 66,710 | -74.3% | 0.00% | – |
| Q2 2023 | $1,236,106 | -48.1% | 259,686 | -37.9% | 0.00% | -100.0% |
| Q1 2023 | $2,383,318 | -19.1% | 418,126 | +43.2% | 0.00% | 0.0% |
| Q4 2022 | $2,945,381 | +5457.3% | 291,911 | +12243.0% | 0.00% | – |
| Q3 2022 | $53,000 | -95.9% | 2,365 | -95.5% | 0.00% | -100.0% |
| Q2 2022 | $1,300,000 | -76.0% | 52,488 | -62.4% | 0.00% | -50.0% |
| Q1 2022 | $5,409,000 | -27.8% | 139,513 | +9.0% | 0.00% | 0.0% |
| Q4 2021 | $7,490,000 | +377.1% | 128,000 | +383.3% | 0.00% | – |
| Q3 2021 | $1,570,000 | +16.0% | 26,485 | +69.7% | 0.00% | – |
| Q2 2021 | $1,354,000 | -63.5% | 15,608 | -65.3% | 0.00% | -100.0% |
| Q1 2021 | $3,710,000 | -53.5% | 44,996 | -48.7% | 0.00% | -66.7% |
| Q4 2020 | $7,977,000 | +2779.8% | 87,721 | +1166.2% | 0.00% | – |
| Q3 2020 | $277,000 | +54.7% | 6,928 | +32.9% | 0.00% | – |
| Q2 2020 | $179,000 | +14.7% | 5,211 | -26.0% | 0.00% | – |
| Q1 2020 | $156,000 | -84.6% | 7,038 | -86.4% | 0.00% | – |
| Q4 2019 | $1,012,000 | -62.0% | 51,722 | -69.8% | 0.00% | -100.0% |
| Q3 2019 | $2,664,000 | +241.5% | 171,505 | +346.3% | 0.00% | – |
| Q2 2019 | $780,000 | +364.3% | 38,431 | +302.3% | 0.00% | – |
| Q1 2019 | $168,000 | -85.1% | 9,554 | -89.1% | 0.00% | -100.0% |
| Q4 2018 | $1,129,000 | +128.5% | 87,952 | +190.2% | 0.00% | – |
| Q3 2018 | $494,000 | -57.0% | 30,310 | -70.1% | 0.00% | – |
| Q2 2018 | $1,150,000 | +1192.1% | 101,410 | +1007.3% | 0.00% | – |
| Q1 2018 | $89,000 | +140.5% | 9,158 | +51.6% | 0.00% | – |
| Q4 2017 | $37,000 | +428.6% | 6,042 | +245.3% | 0.00% | – |
| Q3 2017 | $7,000 | -95.0% | 1,750 | -96.0% | 0.00% | – |
| Q2 2017 | $141,000 | +6950.0% | 43,625 | +5811.2% | 0.00% | – |
| Q4 2016 | $2,000 | -71.4% | 738 | -67.6% | 0.00% | – |
| Q3 2016 | $7,000 | +75.0% | 2,275 | +7.0% | 0.00% | – |
| Q1 2016 | $4,000 | -71.4% | 2,127 | -49.7% | 0.00% | – |
| Q4 2015 | $14,000 | -30.0% | 4,230 | +11.5% | 0.00% | – |
| Q3 2015 | $20,000 | +17.6% | 3,795 | +10.2% | 0.00% | – |
| Q1 2015 | $17,000 | +54.5% | 3,443 | +52.1% | 0.00% | – |
| Q4 2014 | $11,000 | – | 2,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |